2 results
Approved WMOPending
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Approved WMORecruiting
Main objective:Dose Escalation Part:• To assess the safety and tolerability of DF1001, and to determine the Maximum Tolerated Dose (MTD) of DF1001 in patients with Advanced (unresectable, recurrent, or metastatic) solid tumors for whom no effective…